Casdin Capital 13F holdings, Q2 2022
Holdings as of June 30, 2022 · filings on SEC EDGAR · latest filing →
Casdin Capital disclosed 40 US equity positions worth $1.2bn in its Q2 2022 13F filing. The largest position was EQRX INC at 15.7% of the reported book, followed by ALNY and BLFS. Against the Q1 2022 filing, it opened 5 new positions, added to 2 and reduced 19 among the top 40 holdings.
What did Casdin Capital own in Q2 2022? Top 40 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q1 2022 |
|---|---|---|---|---|---|---|---|
| 1 | EQRX INC | 15.7% | $185.4m | 39,527,669 | 0% | held | |
| 2 | ALNY ALNYLAM PHARMACEUTICALS INC | Healthcare | 9.9% | $117.4m | 805,000 | -19% | reduced |
| 3 | BLFS BIOLIFE SOLUTIONS INC | Healthcare | 8.8% | $104.5m | 7,566,292 | 0% | held |
| 4 | RLAY RELAY THERAPEUTICS INC | Healthcare | 5.8% | $68.1m | 4,068,574 | 5% | added |
| 5 | MXCT MAXCYTE INC | 5.6% | $66.1m | 13,971,334 | 0% | held | |
| 6 | 2655787D BLUEPRINT MEDICINES CORP | 4.9% | $58.1m | 1,150,000 | -26% | reduced | |
| 7 | SOMALOGIC INC | 4.7% | $56.0m | 12,389,082 | 0% | held | |
| 8 | FATE FATE THERAPEUTICS INC | Healthcare | 4.4% | $52.0m | 2,100,000 | -38% | reduced |
| 9 | SRPT SAREPTA THERAPEUTICS INC | Healthcare | 4.1% | $48.7m | 650,000 | -19% | reduced |
| 10 | VERVE THERAPEUTICS INC | 4.1% | $48.0m | 3,138,167 | 0% | held | |
| 11 | RVMD REVOLUTION MEDICINES INC | Healthcare | 3.9% | $46.2m | 2,370,000 | 0% | held |
| 12 | DNLI DENALI THERAPEUTICS INC | Healthcare | 3.7% | $44.1m | 1,500,000 | 0% | held |
| 13 | IPSC CENTURY THERAPEUTICS INC | Healthcare | 2.3% | $26.9m | 3,206,380 | 0% | held |
| 14 | ABSI ABSCI CORPORATION | 2.2% | $25.6m | 7,718,593 | 0% | held | |
| 15 | GLOBAL BLOOD THERAPEUTICS IN | 2.2% | $25.6m | 800,000 | -40% | reduced | |
| 16 | WGS SEMA4 HOLDINGS CORP | 1.8% | $20.7m | 16,437,500 | 229% | added | |
| 17 | TNYA TENAYA THERAPEUTICS INC | 1.7% | $20.2m | 3,586,818 | 0% | held | |
| 18 | EXK EXACT SCIENCES CORP | Basic Materials | 1.5% | $17.7m | 450,000 | -66% | reduced |
| 19 | TWST TWIST BIOSCIENCE CORP | Healthcare | 1.5% | $17.5m | 500,000 | -43% | reduced |
| 20 | AGIO AGIOS PHARMACEUTICALS INC | Healthcare | 1.5% | $17.4m | 785,000 | -62% | reduced |
| 21 | TNGX TANGO THERAPEUTICS INC | Healthcare | 1.3% | $15.9m | 3,500,000 | -36% | reduced |
| 22 | BEAM BEAM THERAPEUTICS INC | Healthcare | 1.2% | $14.5m | 375,000 | -54% | reduced |
| 23 | GH GUARDANT HEALTH INC | Healthcare | 0.9% | $11.0m | 272,500 | -35% | reduced |
| 24 | KARUNA THERAPEUTICS INC | 0.9% | $10.8m | 85,000 | – | new | |
| 25 | 2SEVENTY BIO INC | 0.7% | $8.1m | 614,754 | 0% | held | |
| 26 | ABCL ABCELLERA BIOLOGICS INC | Healthcare | 0.7% | $8.0m | 750,000 | – | new |
| 27 | EXSCIENTIA PLC | 0.6% | $7.2m | 663,900 | -7% | reduced | |
| 28 | MIRATI THERAPEUTICS INC | 0.6% | $6.5m | 97,000 | -5% | reduced | |
| 29 | GLUE MONTE ROSA THERAPEUTICS INC | 0.4% | $4.9m | 510,882 | -47% | reduced | |
| 30 | CLDX CELLDEX THERAPEUTICS INC NEW | Healthcare | 0.4% | $4.4m | 165,000 | – | new |
| 31 | PMVP PMV PHARMACEUTICALS INC | 0.4% | $4.3m | 300,000 | – | new | |
| 32 | SGMOQ SANGAMO THERAPEUTICS INC | Healthcare | 0.4% | $4.1m | 1,000,000 | – | new |
| 33 | 4D MOLECULAR THERAPEUTICS IN | 0.3% | $3.9m | 555,455 | 0% | held | |
| 34 | SINGULAR GENOMICS SYSTEMS IN | 0.3% | $3.3m | 865,722 | -40% | reduced | |
| 35 | MAGENTA THERAPEUTICS INC | 0.2% | $2.9m | 2,415,000 | -13% | reduced | |
| 36 | ORIC ORIC PHARMACEUTICALS INC | Healthcare | 0.2% | $2.7m | 601,515 | 0% | held |
| 37 | INVITAE CORP | 0.2% | $2.5m | 1,038,388 | -91% | reduced | |
| 38 | SCIENCE 37 HOLDINGS INC | 0.0% | $452.0k | 225,000 | -88% | reduced | |
| 39 | KRONOS BIO INC | 0.0% | $451.0k | 123,839 | -79% | reduced | |
| 40 | LIANY LIANBIO | 0.0% | $446.0k | 206,415 | 0% | held |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.